Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

With my 1000th post, here's the potential catalysts in May.

May Catalysts

- K presentation with p21 data at ASCO (May 29 – June 2)
- Start of cohort 11 (750 mg/m2)
- Start of B-OM (Phase 2)
- NASDAQ uplisting
- Russell 2000 Index

Q2 Catalysts

- Start of P (Phase 2)
- Start of K + cytarabine (Phase 2)
- B-ABSSSI end-of-phase-2 meeting (late June)

Milestones

- QIDP designation for B-ABSSSI
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 10 (450 mg/m2)
- P Phase 1 primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)

Stock Performances

- 1M: -$0.33 (-10.32%)
- 3M: -$0.74 (-20.27%)
- 6M: -$0.44 (-13.13%)
- 1Y: +$1.11 (+61.67%)

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product